IDEAL-HFHo Project

Cardiometabolic diseases represent a major global health challenge. Cardiovascular diseases account for approximately 20 million deaths per year worldwide, making them the leading cause of mortality. At the same time, nearly 830 million people live with diabetes, and over 1 billion are affected by obesity. 

Homozygous familial hypercholesterolaemia (HFHo), at the heart of IHU ICAN’s IDEAL-HFHo project, is an extremely rare genetic disease with an estimated prevalence of approximately 1 in 300,000 people, corresponding to a few tens of thousands of patients worldwide. This condition leads to very early coronary atherosclerosis and requires innovative therapeutic approaches. 

In this context, L’Institut Servier supports the IDEAL-HFHo project coordinated by Dr Antonio Gallo. The programme aims to evaluate the impact of angiopoietin-like 3 protein inhibition on HDL function, inflammatory biomarkers, and the progression of coronary and aortic plaques. It is based on a combination of OMICS analyses, HDL functional biology and quantitative cardiovascular imaging, with implementation planned from 2025 to 2031. 

This support contributes to the advancement of knowledge on cardiometabolic diseases and the development of new management strategies.